Intellia Therapeutics, Inc. (0JBU.L)
USD 6.17
(-11.96%)
USD 6.17
(-11.96%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -111.4 Million USD | 71.64% |
| 2022 | -392.8 Million USD | -695.42% |
| 2021 | -49.38 Million USD | 59.09% |
| 2020 | -120.71 Million USD | -210.71% |
| 2019 | -38.85 Million USD | 33.99% |
| 2018 | -58.85 Million USD | 82.72% |
| 2017 | -340.67 Million USD | -24.76% |
| 2016 | -273.06 Million USD | -260.17% |
| 2015 | -75.81 Million USD | -670.1% |
| 2014 | -9.84 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -24.55 Million USD | 59.82% |
| 2024 Q1 | -61.11 Million USD | 45.14% |
| 2023 Q3 | -49.69 Million USD | -0.44% |
| 2023 Q4 | -111.4 Million USD | -124.19% |
| 2023 FY | -111.4 Million USD | 71.64% |
| 2023 Q1 | -168.02 Million USD | 57.23% |
| 2023 Q2 | -49.47 Million USD | 70.55% |
| 2022 Q2 | -78.21 Million USD | -27.05% |
| 2022 Q1 | -61.56 Million USD | -24.67% |
| 2022 Q4 | -392.8 Million USD | -802.04% |
| 2022 FY | -392.8 Million USD | -695.42% |
| 2022 Q3 | -43.54 Million USD | 44.33% |
| 2021 Q2 | -59.2 Million USD | 13.94% |
| 2021 Q4 | -49.38 Million USD | 80.92% |
| 2021 Q1 | -68.79 Million USD | 43.01% |
| 2021 FY | -49.38 Million USD | 59.09% |
| 2021 Q3 | -258.75 Million USD | -337.05% |
| 2020 Q4 | -120.71 Million USD | 23.38% |
| 2020 FY | -120.71 Million USD | -210.71% |
| 2020 Q3 | -157.54 Million USD | 53.46% |
| 2020 Q2 | -338.5 Million USD | -497.74% |
| 2020 Q1 | -56.63 Million USD | -45.76% |
| 2019 Q1 | -27.58 Million USD | 53.13% |
| 2019 FY | -38.85 Million USD | 33.99% |
| 2019 Q4 | -38.85 Million USD | -106.73% |
| 2019 Q3 | -18.79 Million USD | 36.23% |
| 2019 Q2 | -29.47 Million USD | -6.84% |
| 2018 Q1 | -327.77 Million USD | 3.79% |
| 2018 FY | -58.85 Million USD | 82.72% |
| 2018 Q4 | -58.85 Million USD | 79.93% |
| 2018 Q3 | -293.24 Million USD | 4.02% |
| 2018 Q2 | -305.53 Million USD | 6.79% |
| 2017 Q4 | -340.67 Million USD | -53.28% |
| 2017 FY | -340.67 Million USD | -24.76% |
| 2017 Q1 | -257.55 Million USD | 5.68% |
| 2017 Q2 | -241.04 Million USD | 6.41% |
| 2017 Q3 | -222.26 Million USD | 7.79% |
| 2016 Q4 | -273.06 Million USD | 6.04% |
| 2016 FY | -273.06 Million USD | -260.17% |
| 2016 Q2 | -300.68 Million USD | -368.42% |
| 2016 Q3 | -290.61 Million USD | 3.35% |
| 2016 Q1 | -64.19 Million USD | 15.33% |
| 2015 Q2 | -19.76 Million USD | -300.76% |
| 2015 Q1 | 9.84 Million USD | 200.0% |
| 2015 FY | -75.81 Million USD | -670.1% |
| 2015 Q4 | -75.81 Million USD | 8.23% |
| 2015 Q3 | -82.61 Million USD | -317.97% |
| 2014 FY | -9.84 Million USD | 0.0% |
| 2014 Q4 | -9.84 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | -8.209% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | -256.863% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 156.245% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 449.387% |
| bluebird bio, Inc. | 108.57 Million USD | 202.608% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -1135.603% |
| Imunon, Inc. | -4.69 Million USD | -2270.622% |
| Editas Medicine, Inc. | -87.11 Million USD | -27.878% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.867% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 105.31% |
| Myriad Genetics, Inc. | 88.1 Million USD | 226.449% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 162.832% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -232.275% |
| Verastem, Inc. | -37.27 Million USD | -198.841% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 101.353% |
| Waters Corporation | 1.96 Billion USD | 105.683% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.415% |
| Biogen Inc. | 6.28 Billion USD | 101.772% |
| Nektar Therapeutics | 210.24 Million USD | 152.988% |
| Perrigo Company plc | 3.32 Billion USD | 103.353% |
| Dynavax Technologies Corporation | 106.63 Million USD | 204.47% |
| Illumina, Inc. | 1.21 Billion USD | 109.176% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 1698.748% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 2.183% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 176.789% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 1650.049% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 129.413% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -1469.042% |
| Evolus, Inc. | 63.7 Million USD | 274.863% |
| Adicet Bio, Inc. | -142 Million USD | 21.552% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | -202.69% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -311.077% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 124.287% |
| FibroGen, Inc. | 56.76 Million USD | 296.244% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 109.729% |
| OPKO Health, Inc. | 230.68 Million USD | 148.292% |
| Homology Medicines, Inc. | 18.43 Million USD | 704.231% |
| Geron Corporation | 14.76 Million USD | 854.705% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 107.027% |
| Exelixis, Inc. | -73.05 Million USD | -52.501% |
| Viking Therapeutics, Inc. | -54.25 Million USD | -105.327% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 26.236% |
| Zoetis Inc. | 4.76 Billion USD | 102.339% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 44.249% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -1006.166% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 98.835% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -664.494% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 110.567% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 111.504% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 17.724% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 108.067% |
| Blueprint Medicines Corporation | 702.83 Million USD | 115.85% |
| Insmed Incorporated | 721.62 Million USD | 115.438% |
| TG Therapeutics, Inc. | 17.86 Million USD | 723.682% |
| Incyte Corporation | -3.17 Billion USD | 96.491% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 114.547% |